Boston Scientific announces EU and US approval of new pacemakers

12 May 2008

Boston Scientific Corporation (NYSE:BSX) has announced US Food and Drug Administration (FDA) and CE Mark approval of its Altrua family of pacemakers. The products are

The Altrua is Boston Scientific's most advanced pacemaker and delivers enhanced therapies while maintaining its small size and battery longevity. It is the first Boston Scientific-branded pacemaker to treat bradycardia, a condition in which the heart beats too slowly (usually less than 60 beats per minute) depriving the body of sufficient oxygen.

"FDA approval of Boston Scientific's Altrua family of pacemakers — especially following the European approval of Altrua — further demonstrates the significant progress we have made rebuilding our CRM organization and reinvigorating our product pipeline," said Fred Colen, Executive Vice President, Operations and Technology, Cardiac Rhythm Management. "Pacemakers are the most implanted device in the cardiac rhythm management industry and we look forward to making the Altrua family broadly available to physicians and their patients."

To top